Table 1.

mPSC characteristics

Condition	Amplitude AMPA	Frequency AMPA	Decay AMPA	n	Amplitude GABA	Frequency GABA	Decay GABA	n
Control E8–E10	8.1 ± 0.4	0.49 ± 0.11	4.3 ± 0.9	7	13.0 ± 0.6	0.56 ± 0.32	30.4 ± 10.9	7
Dhbe E8–E10	10.4 ± 0.6**	0.59 ± 0.15	3.9 ± 0.9	8	16.6 ± 1.3*	0.51 ± 0.11	25.5 ± 10.2	8
Gabazine E8–E10	10.7 ± 1.0**	0.59 ± 0.17	4.1 ± 0.5	9	19.2 ± 2.1***	0.49 ± 0.11	26.6 ± 3.7	9
Gabazine DHBE E8–E10	10.5 ± 0.7**	0.44 ± 0.19	4.3 ± 1.1	12	16.4 ± 1.3*	0.42 ± 0.27	27.3 ± 2.7	12
Gabazine nicotine E8–E10	10.8 ± 0.5***	0.33 ± 0.11	3.9 ± 0.6	14	18.6 ± 0.7***	0.50 ± 0.15	25.8 ± 11.5	17
Lidocaine E8–E10	12.6 ± 1.3***	1.11 ± 0.37	4.4 ± 1.1	8	17.3 ± 2.8*	0.47 ± 0.18	22.3 ± 10.3	8
Lidocaine nicotine E8–E10	7.0 ± 0.4	0.58 ± 0.12	4.2 ± 1.4	9	9.0 ± 0.3*	0.50 ± 0.22	23.5 ± 6.6	9
Control E8 12 h	17.7 ± 1.5	0.41 ± 0.09	3.8 ± 0.4	7	20.7 ± 1.3	0.17 ± 0.06	18.5 ± 1.6	7
Nicotine E8 12 h	9.5 ± 0.7**	0.27 ± 0.08	4.8 ± 0.2	7	16.8 ± 2.0	0.43 ± 0.08*	20.6 ± 1.3	7
Control acute E8	10.9 ± 1.0	0.28 ± 0.04	4.1 ± 0.2	10	15.4 ± 0.9	0.32 ± 0.05	20.8 ± 1.8	11
Nicotine acute E8	10.4 ± 0.9	0.44 ± 0.11	5.7 ± 1.3	7	17.9 ± 1.1	0.62 ± 0.08**	19.2 ± 0.8	7
DCG-IV acute E8	12.0 ± 1.3	0.46 ± 0.16	3.3 ± 0.9*	9	16.1 ± 1.7	0.17 ± 0.05*	26.1 ± 1.1*	9
Control E8–E10	9.0 ± 1.0	0.39 ± 0.07	4.1 ± 0.2	7	15.0 ± 2.7	0.40 ± 0.11	20.6 ± 1.2	7
Dcg E8–E10	13.2 ± 0.8**	0.42 ± 0.16	4.5 ± 0.3	16	21.8 ± 1.3**	0.54 ± 0.10	20.6 ± 1.0	16
Nicotine E8–E10	7.0 ± 0.3*	0.51 ± 0.14	4.6 ± 0.3	11	10.3 ± 0.5*	0.32 ± 0.07	20.2 ± 2.5	11

Amplitude, frequency, decay constant of AMPA, and GABA mPSCs are shown for different conditions. The numbers of cells for each condition are also shown, along with significant differences (*p < 0.05; **p < 0.01; ***p < 0.001). Values are clustered into four groups for statistical comparisons. The first group includes embryos treated with DHβE, gabazine, DHβE/gabazine, nicotine/gabazine, lidocaine, lidocaine/nicotine, or control from E8–E10 (GABA mPSC amplitude: ANOVA with post hoc Tukey test for multiple comparisons; GABA mPSC frequency and AMPA mPSC amplitude and frequency: Kruskal–Wallis nonparametric test with Conover–Iman procedure for multiple comparisons). The second group includes embryos treated with nicotine for 12 h or control (Student's t test was used for all parameters except AMPA mPSC decay: Kruskal–Wallis nonparametric test). The third group includes embryos acutely treated with nicotine, DCG-IV, or controls at E8 (AMPA mPSC amplitude, GABA mPSC decay: ANOVA with post hoc Tukey test for multiple comparisons; all other parameters: Kruskal–Wallis nonparametric test with Conover–Iman procedure for multiple comparisons). The fourth group includes embryos treated with nicotine, DCG-IV, or controls from E8–E10 (all Kruskal–Wallis nonparametric test with Conover–Iman procedure for multiple comparisons).